Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite and will bring clinical, strategic and financial leadership to biotech’s board
BOSTON–(BUSINESS WIRE)–1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.
“Having served on many biotechnology company boards, I am excited to help guide the direction of 1910 Genetics”Post this
“Effective corporate governance requires a board with substantial expertise in the domains you aim to advance, and a shared commitment to deliberating and making informed decisions,” said Jen Nwankwo, PhD, Founder & CEO of1910 Genetics. “As a successful biotech investor and visionary collaborator, Shaan is a superstar addition to our board, who will no doubt influence our trajectory for continued success. This appointment will strengthen our ability to navigate any perceived headwinds headed into 2024, which is poised to be a pivotal year for 1910 Genetics.”
Dr. Gandhi is currently head of strategic partnerships for Pfizer Ignite where he works closely with biotechnology companies to create opportunities for collaboration that accelerate therapeutic innovation. He was previously a Director at Northpond Ventures where he led its biotechnology investment team, and a Principal at Longwood Fund, where he co-founded and was President of Pyxis Oncology (NASDAQ: PYXS), a company focused on developing antibody-drug conjugates (ADCs) and monoclonal antibody immunotherapies for patients with cancer.
Dr. Gandhi joins a board that already includes:
- Jen Nwankwo, PhD, Founder & CEO, 1910 Genetics;
- Desney Tan, PhD, VP and Managing Director of Microsoft Research Lab;
- Phyllis Whiteley, PhD, Venture Partner at Playground Global; and
- Michael Stewart, PhD, Partner at M12-Microsoft’s Venture Fund
“Having served on many biotechnology company boards, I am excited to help guide the direction of 1910 Genetics,” said Dr. Gandhi. “1910 Genetics has clear line of sight to significant value creation in 2024 and beyond due to its unique approach to drug discovery enabled by AI, data and optimized compute, its ability to partner with industry leaders, and a dedicated, experienced, and innovative team, led by Jen Nwankwo. I can’t wait to see what the future holds for this team and to help support their work to make a mark in healthcare and the life sciences.”
For more information visit 1910Genetics.com or follow us on LinkedIn.
About 1910 Genetics
1910 Genetics is the only biotech company advancing small and large molecule drug discovery with an automated, multimodal AI platform. We integrate AI with three proprietary data streams – computational data, wet lab ground truth biological data and wet lab proxy biological data – to deliver novel drug candidates to leading pharma and tech partners, and advance our own pipeline for neurological, autoimmune diseases, and cancer. 1910 was launched in 2021 with a combined seed and Series A funding of $26.1M backed by M12-Microsoft’s Venture Fund, Playground Global, OpenAI’s Sam Altman, and other leading investors. We have since established our HQ and lab facilities in Boston’s Seaport District and continue to hire a world-class team. To learn more visit 1910Genetics.com.
Contacts
Amanda Guisbond
[email protected]
